
Beyond the Binary: Unpacking Molecular Diversity in PMMR Endometrial Cancer
Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial
Editorial: Hitting the mark—or missing it? The promise and peril of biomarkers in endometrial cancer
Hosted by:
Amanda Nickles Fader, MD; Johns Hopkins Medicine Baltimore, MD, USA
Featuring:
Kathleen Moore, MD; Gynecologic Cancer Clinic, Stephenson Cancer Center at the University of Oklahoma Medical Center, Oklahoma City, OK, USA
Ramez N Eskander, MD; Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, UC San Diego, USA
Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
Altri episodi di "Listen to Gynecologic Oncology"



Non perdere nemmeno un episodio di “Listen to Gynecologic Oncology”. Iscriviti all'app gratuita GetPodcast.








